Approximately 20% were discontinued due to adverse experiences.Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Use only the number of drops your doctor has prescribed. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), antihypertensives and/or cardiac glycosides is advised.Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15%, sterile, is a relatively selective alpha-2 adrenergic receptor agonist (topical intraocular pressure lowering agent).. Select one or more newsletters to continue. Patients prescribed IOP-lowering medication should be routinely monitored for IOP.Information for Patients:   The preservative in brimonidine tartrate ophthalmic solution 0.2%, benzalkonium chloride, may be absorbed by soft contact lenses. Brimonidine tartrate has the action of lowering intraocular pressure with minimal effect on cardiovascular and pulmonary parameters.In comparative clinical studies with timolol 0.5%, lasting up to one year, the IOP lowering effect of brimonidine tartrate ophthalmic solution 0.2% was approximately 4-6 mmHg compared with approximately 6 mmHg for timolol. An overdose of brimonidine ophthalmic is not expected to be dangerous. It has an osmolality of 280-330 mOsml/kg and a pH of 5.6-6.6 The structural formula isChemical Name: 5-bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate.CAS Number 59803-98-4Each … It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.General:   Although brimonidine tartrate ophthalmic solution 0.2% had minimal effect on blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.Brimonidine tartrate ophthalmic solution 0.2% has not been studied in patients with hepatic or renal impairment; caution should be used in treating such patients.Brimonidine tartrate ophthalmic solution 0.2% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans.During the studies there was a loss of effect in some patients. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.Carcinogenesis, mutagenesis, impairment of fertility:   No compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.Brimonidine Tartrate Ophthalmic Solution 0.2% is supplied sterile in a plastic bottle with a controlled drop tip in the following sizes:DO NOT USE IF IMPRINTED "Protective Seal" WITH YELLOW IS NOT INTACT.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Call your doctor for medical advice about side effects. Ask your doctor before using Tell your doctor about all your other medicines, especially:This list is not complete. The structural formula of brimonidine tartrate is: It has an osmolality of 280-330 mOsml/kg and a pH of 5.6-6.6 The structural formula isChemical Name:   5-bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate.INACTIVES:   Citric Acid, Polyvinyl Alcohol, Sodium Chloride, Sodium Citrate, Purified Water. Not all possible drug interactions are listed here.Your pharmacist can provide more information about brimonidine ophthalmic.Copyright © 2020 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment.